Krazati (adagrasib)

Indications and Usage: 

Krazati is a breakthrough inhibitor of the RAS GTPase family designed to provide hope and effective treatment for adult patients battling KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This treatment is indicated for patients who have previously undergone at least one systemic therapy, as confirmed by an FDA-approved test. It’s important to note that this indication has been granted accelerated approval based on objective response rate (ORR) and duration of response (DOR). Further confirmation of clinical benefit may be required in confirmatory trials.

Dosage and Administration:

• Recommended Dosage: 600 mg orally twice daily.
• Tablets are to be swallowed whole, with or without food.

Contraindications:

• None

• Gastrointestinal Adverse Reactions: Patients should be closely monitored for symptoms like diarrhea, nausea, and vomiting, with appropriate supportive care as needed. Dose adjustments may be required based on the severity of symptoms.
  
• QTc Interval Prolongation: Avoid concurrent use of Krazati with products known to prolong the QTc interval. Regularly monitor ECG and electrolytes in at-risk patients or those taking QT-prolonging medications. Adjust the dose or discontinue treatment as necessary.
  
• Hepatotoxicity: Before starting Krazati and monthly for three months after, as well as when clinically indicated, conduct liver laboratory tests. Dose adjustments, temporary suspension, or permanent discontinuation may be necessary depending on the severity of hepatotoxicity.
  
• Interstitial Lung Disease / Pneumonitis: Monitor for the development of new or worsening respiratory symptoms. If suspected, temporarily withhold Krazati and discontinue if no alternative causes of ILD/pneumonitis are identified.

Adverse Reactions:

• The most common adverse reactions (≥ 25%) include nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, and decreased appetite.
  
• Common Grade 3 or 4 laboratory abnormalities (≥ 2%) consist of decreased lymphocytes, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, decreased leukocytes, decreased neutrophils, and increased alkaline phosphatase.

For detailed information on clinically significant drug interactions with Krazati , please refer to the full prescribing information. Key points to note include avoiding concomitant use with strong CYP3A4 inducers or inhibitors, sensitive CYP3A4 substrates, sensitive CYP2C9 or CYP2D6 substrates, P-gp substrates, and drugs that prolong the QT interval. These precautions help ensure the safety and effectiveness of the treatment.

Indian Pharma Network is proficient in sourcing Krazati from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Indian Pharma Network (IPN) is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities

What is Krazati used for?

Krazati treats KRAS G12C-mutated non-small cell lung cancer (NSCLC) in adults who’ve had prior systemic therapy.

How does Krazati work?

Krazati inhibits the KRAS G12C mutation, impeding cancer cell growth.

Who is eligible for Krazati?

Adults with KRAS G12C-mutated NSCLC confirmed by an FDA-approved test and who’ve had prior therapy.

What are common side effects?

Common side effects include nausea, diarrhea, fatigue, and more. Discuss with your healthcare provider.

Is Krazati available in India?

Yes, it’s available with a valid doctor’s prescription and required documentation.

Is Krazati FDA approved?

Krazati got approved by the FDA in 2022.